This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a multicenter randomized, double blind, comparative trial of the anti-epilepsy drugs (AED) ethosuximide (ETX), lamotrigine (LTG) and valproic acid (VPA) as initial monotherapy for children with Childhood Absence Epilepsy (CAE). Treatment success will be defined as a composite of seizure control and short and long-term tolerability. Factors potentially predictive for the most common treatment limitations of each AED will be studied, including the PG, PK and clinical profiles of patients developing LTG associated rash, VPA induced weight gain or ETX-associated gastrointestinal side effects.
Showing the most recent 10 out of 563 publications